loading page

Ovarian cancer cell death induced by non-genomic action of progesterone and its receptor agonist via membrane receptors
  • +7
  • Takahiro Koyanagi,
  • Yasushi Saga,
  • Yoshifumi Takahashi,
  • Kohei Tamura,
  • Takahiro Yoshiba,
  • Suzuyo Takahashi,
  • Akiyo Taneichi,
  • Yuji Takei,
  • Hiroaki Mizukami,
  • Hiroyuki Fujiwara
Takahiro Koyanagi
Jichi Medical University
Author Profile
Yasushi Saga
Jichi Medical University

Corresponding Author:[email protected]

Author Profile
Yoshifumi Takahashi
Jichi Medical University
Author Profile
Kohei Tamura
Jichi Medical University
Author Profile
Takahiro Yoshiba
Jichi Medical University
Author Profile
Suzuyo Takahashi
Jichi Medical University
Author Profile
Akiyo Taneichi
Jichi Medical University
Author Profile
Yuji Takei
Jichi Medical University
Author Profile
Hiroaki Mizukami
Jichi Medical University
Author Profile
Hiroyuki Fujiwara
Jichi Medical University
Author Profile

Abstract

Background and Aims: Progesterone therapy is a relatively inexpensive treatment option for endometrial and breast cancers, with few side effects. Two signaling pathways usually mediate the physiological effects of progesterone, namely genomic and non-genomic actions. Genomic action occurs slowly via the nuclear progesterone receptor (PR), whereas the membrane progesterone receptor (mPR) induces rapid non-genomic action. We investigated the effects of progesterone and various PR agonists on ovarian cancer cells. Methods: PR expression of six serous ovarian cancer cell lines was examined by western blotting, and mPR expression was examined by RT-qPCR. PR-negative and mPR-positive ovarian cancer cells were exposed to progesterone and seven types of PR agonists (medroxyprogesterone acetate [MPA], dehydroepiandrosterone, dienogest, levonorgestrel, drospirenone, pregnenolone, and allopregnanolone) at 10–400 μM, and viable cell counts after exposure for 30 min were measured using the water soluble tetrazolium (WST-1) assay. Ovarian cancer cell lines were exposed to 100 μM progesterone, and the expression of BAX, a pro-apoptotic protein, after 1-5 min was examined by western blotting. Results: Western blotting detected no PR expression in the six serous ovarian cancer cell lines. In contrast, RT-qPCR detected mPR expression in all six serous ovarian cancer cell lines. Progesterone and MPA induced cell death in all tested ovarian cancer cell lines in a concentration-dependent manner, whereas no effect was observed for other PR agonists. Western blotting revealed that pro-apoptotic protein BAX expression occurred 1 min after exposure to progesterone, suggesting that the cytocidal effects are mediated by rapid non-genomic action. Conclusions: MPA, like progesterone exhibited a rapid cytocidal effect on PR-negative ovarian cancer cells through non-genomic action. Progesterone and MPA could be novel treatment modalities for ovarian cancer. Keywords: genomics, medroxyprogesterone acetate, ovarian cancer, progesterone, progesterone receptor
03 Jun 2023Submitted to Cancer Reports
15 Jun 2023Submission Checks Completed
15 Jun 2023Assigned to Editor
15 Jun 2023Review(s) Completed, Editorial Evaluation Pending
29 Jun 2023Reviewer(s) Assigned
31 Jul 2023Editorial Decision: Revise Major
28 Aug 20231st Revision Received
29 Aug 2023Submission Checks Completed
29 Aug 2023Assigned to Editor
29 Aug 2023Review(s) Completed, Editorial Evaluation Pending
05 Sep 2023Reviewer(s) Assigned
02 Oct 2023Editorial Decision: Revise Major
09 Oct 20232nd Revision Received
19 Oct 2023Review(s) Completed, Editorial Evaluation Pending
06 Nov 2023Editorial Decision: Accept